KMPH KemPharm, Inc.

KemPharm, Inc., a specialty pharmaceutical company, discovers and develops various proprietary prodrugs in the United States. Its product candidate includes KP415 and KP484 for the treatment of attention deficit hyperactivity disorder; and KP879 for the treatment of stimulant use disorder. The company also provides APADAZ, an immediate-release combination product candidate of benzhydrocodone and acetaminophen to treat the short-term management of acute pain. It has a collaboration agreement with KVK-Tech, Inc. to manufacture and commercialize APADAZ. The company was founded in 2006 and is headquartered in Celebration, Florida.

$8.13  +0.41 (5.31%)
As of 12/06/2021 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  12/31/1969
Outstanding shares:  35,319,426
Average volume:  470,430
Market cap:   $272,665,969
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    488445206
ISIN:        US4884452065
Sedol:      BLFBZ32
Valuation   (See tab for details)
PE ratio:   -4.41
PB ratio:   2.18
PS ratio:   9.59
Return on equity:   -8.13%
Net income %:   -37.66%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy